NEW YORK, March. 13, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offeringreports on AEZS, AFMD, AGEN, and AGIO which can be accessed for free by signing up to www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com monitors Aeterna Zentaris Inc. (NASDAQ: AEZS), Affimed N.V. (NASDAQ: AFMD),
On Monday, shares in Summerville, South Carolina headquartered Aeterna Zentaris Inc. saw a slight decline of 0.06%, ending the day at $1.69. The stock recorded a trading volume of 70,819 shares. The Company's shares are trading below their 200-day moving average by 9.00%. Moreover, shares of Aeterna Zentaris, which engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health, have a Relative Strength Index (RSI) of 37.18.
On March 05th, 2018, Aeterna Zentaris announced the appointment of James Clavijo as CFO, effective that day. Mr. Clavijo joins the Company from Tri-Source Pharma, where he most recently served as CFO. Get the full research report on AEZS for free by clicking below at:
Shares in Heidelberg, Germany headquartered Affimed N.V. ended the day 2.17% lower at $2.25 with a total trading volume of 634,191 shares. In the previous three months, the stock has gained 18.42%. The Company's shares are trading above their 50-day and 200-day moving averages by 25.30% and 12.57%, respectively. Furthermore, shares of Affimed, which focuses on discovering and developing cancer immunotherapies in Germany and internationally, have an RSI of 56.82.
On March 08th, 2018, Affimed announced that Dr. Adi Hoess, CEO, will present at the Cowen and Company 38th Annual Health Care Conference on March 14th, 2018, at 10:00 a.m. ET. The live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Company's website. Today's complimentary research report on AFMD is accessible at:
At the close of trading on Monday, shares in Lexington, Massachusetts headquartered Agenus Inc. finished 1.39% lower at $5.67. A total volume of 1.91 million shares was traded, which was above their three months average volume of 1.48 million shares. The stock has surged 52.83% in the last month, 56.63% over the previous three months, and 37.45% over the past year. The Company's shares are trading above their 50-day and 200-day moving averages by 34.11% and 41.05%, respectively. Additionally, shares of Agenus, which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer, have an RSI of 68.74.
On March 07th, 2018, Agenus announced that it will release its Q4 and full-year 2017 financial results before the market opens on March 15th, 2018. In connection with the earnings release, Company executives will host a conference call and live audio webcast at 11:00 a.m. ET the same day to discuss the results and provide an update. Register now for your free research document on AGEN at:
Cambridge, Massachusetts-based Agios Pharmaceuticals Inc.'s shares recorded a trading volume of 225,427 shares at the end of yesterday's session. The stock closed the day 0.68% higher at $84.52. The Company's shares have advanced 13.82% in the past month, 38.94% in the previous three months, and 61.79% over the past year. The stock is trading above its 50-day and 200-day moving averages by 13.19% and 33.28%, respectively. Additionally, shares of Agios Pharma, which engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the US, have an RSI of 63.54.
On February 15th, 2018, research firm SunTrust reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $80 a share to $101 a share.
On February 15th, 2018, Agios Pharma announced that the US FDA has accepted the Company's New Drug Application for ivosidenib for the treatment of patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 1 mutation. The FDA's Priority Review status accelerates the review time from ten months to a goal of six months from the day of filing acceptance and is given to drugs that may offer major advances in treatment or may provide a treatment where no adequate therapy exists. Click on the link below and see our free report AGIO at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/whats-happening-with-these-biotech-stocks----aeterna-zentaris-affimed-agenus-and-agios-pharma-300612979.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...View All